DelNova is developing proprietary therapies by leveraging advances in drug delivery technology. They have identified an anticholinesterase class of drugs as a means of accelerating muscle recovery by indirectly increasing the neurotransmitter deficit caused by botulinum toxin.

Biotechnology

Delivery

Health Care

Staffing & Recruiting

Delnova

Mary Gardner

Hannah Roddy

Dimas Jiménez

Steven Yoelin

Sameer B. Shah

The Scientific Team at DelNova is responsible for researching and developing novel drug delivery systems based on anticholinesterase compounds to enhance muscle recovery. This team collaborates to design experiments, analyze data, and guide the formulation of therapies that counteract the neurotransmitter deficits caused by botulinum toxin.

Scientific Team

Leadership Team

Scientific Team

About

Team members

Other teams at Delnova

Leadership Team